Publication | Closed Access

Two-year results of reduced-fluence photodynamic therapy combined with intravitreal ranibizumab for typical age-related macular degeneration and polypoidal choroidal vasculopathy

Ocular DiseaseVitreous BodyOphthalmologyTwo-year ResultsPhotodynamic TherapyAge-related DiseasesGlaucomaReduced-fluence Photodynamic TherapyPhotosensitizersMedicineRadiation OncologyIntravitreal RanibizumabHealth Sciences